BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hussein NR, Saleema ZSM, Abd QH. Direct Acting Antiviral Treatment for Patients with End-Stage Kidney Disease with Acute HCV Infection. Mediterr J Hematol Infect Dis 2019;11:e2019034. [PMID: 31205638 DOI: 10.4084/MJHID.2019.034] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Hussein NR, M Saleem ZS, Ibrahim N, Musa DH, Naqid IA. The impact of COVID-19 pandemic on the care of patients with kidney diseases in Duhok City, Kurdistan Region of Iraq. Diabetes Metab Syndr 2020;14:1551-3. [PMID: 32846367 DOI: 10.1016/j.dsx.2020.08.013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
2 Ji Q, Chu X, Zhou Y, Liu X, Zhao W, Ye W. Safety and efficacy of grazoprevir/elbasvir in the treatment of acute hepatitis C in hemodialysis patients. J Med Virol 2021. [PMID: 34599755 DOI: 10.1002/jmv.27374] [Reference Citation Analysis]
3 Amirsardari Z, Rahmani F, Rezaei N. Cognitive impairments in HCV infection: From pathogenesis to neuroimaging. J Clin Exp Neuropsychol 2019;41:987-1000. [PMID: 31405320 DOI: 10.1080/13803395.2019.1652728] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
4 Shehadeh F, Kalligeros M, Byrd K, Shemin D, Mylonakis E, Martin P, D'Agata EMC. Efficacy and safety of sofosbuvir in the treatment of hep C among patients on hemodialysis: a systematic review and meta-analysis. Sci Rep 2020;10:14332. [PMID: 32868869 DOI: 10.1038/s41598-020-71205-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]